These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

478 related articles for article (PubMed ID: 8701189)

  • 1. [Left-ventricular hypertrophy as a cardiac risk factor: role of the renin-angiotensin-aldosterone system].
    Erne P
    Praxis (Bern 1994); 1996 Feb; 85(8):227-33. PubMed ID: 8701189
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Spironolactone: renaissance of anti-aldosterone therapy in heart failure?].
    Brilla CG; Schencking M; Scheer C; Rupp H
    Praxis (Bern 1994); 1997 Apr; 86(14):566-74. PubMed ID: 9198851
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Aldosterone antagonism in addition to angiotensin-converting enzyme inhibitors in heart failure.
    Bauersachs J; Fraccarollo D
    Minerva Cardioangiol; 2003 Apr; 51(2):155-64. PubMed ID: 12783071
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Role of angiotensin-converting enzyme inhibitors, angiotensin II receptor blockers, and aldosterone antagonists in the prevention of atrial and ventricular arrhythmias.
    Makkar KM; Sanoski CA; Spinler SA
    Pharmacotherapy; 2009 Jan; 29(1):31-48. PubMed ID: 19113795
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cardioprotection by aldosterone receptor antagonism in heart failure. Part I. The role of aldosterone in heart failure.
    Dieterich HA; Wendt C; Saborowski F
    Fiziol Cheloveka; 2005; 31(6):97-105. PubMed ID: 16366159
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Role of aldosterone in angiotensin II-induced cardiac and aortic inflammation, fibrosis, and hypertrophy.
    Neves MF; Amiri F; Virdis A; Diep QN; Schiffrin EL;
    Can J Physiol Pharmacol; 2005 Nov; 83(11):999-1006. PubMed ID: 16391708
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Determinants of increased angiotensin II levels in severe chronic heart failure patients despite ACE inhibition.
    van de Wal RM; Plokker HW; Lok DJ; Boomsma F; van der Horst FA; van Veldhuisen DJ; van Gilst WH; Voors AA
    Int J Cardiol; 2006 Jan; 106(3):367-72. PubMed ID: 16337046
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Role of the cardiac renin-angiotensin system in hypertensive heart disease].
    Holmer SR; Riegger GA
    Herz; 1995 Oct; 20(5):322-9. PubMed ID: 7498879
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Angiotensin-converting enzyme inhibitors and angiotensin II receptor antagonists in the treatment of heart failure caused by left ventricular systolic dysfunction.
    Sander GE; McKinnie JJ; Greenberg SS; Giles TD
    Prog Cardiovasc Dis; 1999; 41(4):265-300. PubMed ID: 10362349
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The impact of left ventricular assist device-induced left ventricular unloading on the myocardial renin-angiotensin-aldosterone system: therapeutic consequences?
    Klotz S; Burkhoff D; Garrelds IM; Boomsma F; Danser AH
    Eur Heart J; 2009 Apr; 30(7):805-12. PubMed ID: 19223317
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Angiotensin II receptor antagonists and heart failure: angiotensin-converting-enzyme inhibitors remain the first-line option.
    Prescrire Int; 2005 Oct; 14(79):180-6. PubMed ID: 16285075
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Growth stimulating properties of angiotensin II on the heart: consequences for therapy of heart failure].
    Schunkert H; Holmer SR; Riegger G
    Z Kardiol; 1993; 82 Suppl 4():1-6. PubMed ID: 8147057
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Pathophysiology of left ventricular hypertrophy in arterial hypertension].
    Vallotton MB; Braconi-Quintaje S; Lang U
    Praxis (Bern 1994); 1997 Feb; 86(7):234-7. PubMed ID: 9139339
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Hypertension mega-trials with cardiovascular end points: effect of angiotensin-converting enzyme inhibitors and angiotensin receptor blockers.
    Kjeldsen SE; Julius S
    Am Heart J; 2004 Nov; 148(5):747-54. PubMed ID: 15523303
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effects of renin-angiotensin system inhibition on end-organ protection: can we do better?
    Weir MR
    Clin Ther; 2007 Sep; 29(9):1803-24. PubMed ID: 18035185
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The renin-angiotensin system in the heart and vascular wall: new therapeutic aspects.
    Falkenhahn M; Gohlke P; Paul M; Stoll M; Unger T
    J Cardiovasc Pharmacol; 1994; 24 Suppl 2():S6-13. PubMed ID: 7898096
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cardiac renin-angiotensin system: role in development of pressure-overload hypertrophy.
    Lorell BH
    Can J Cardiol; 1995 Aug; 11 Suppl F():7F-12F. PubMed ID: 7664219
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Collagen network of the myocardium: function, structural remodeling and regulatory mechanisms.
    Weber KT; Sun Y; Tyagi SC; Cleutjens JP
    J Mol Cell Cardiol; 1994 Mar; 26(3):279-92. PubMed ID: 8028011
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Cardiac structure-function relationship and the renin-angiotensin-aldosterone system in hypertensive heart disease].
    Funck RC; Wilke A; Rupp H; Maisch B; Brilla CG
    Herz; 1995 Oct; 20(5):330-9. PubMed ID: 7498880
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Induction of cardiac fibrosis by aldosterone.
    Lijnen P; Petrov V
    J Mol Cell Cardiol; 2000 Jun; 32(6):865-79. PubMed ID: 10888242
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 24.